ZT007
/ Beijing QL Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 08, 2025
A novel GLP-1/GDF15 dual-agonist reduces hepatic inflammation and fibrosis in murine models of chemical-induced liver fibrosis and metabolic associated steatohepatitis (MASH)
(EASL 2025)
- "GLP-1/GDF15 dual-agonist showed a synergistic effect in reducing hepatic inflammation and fibrosis was observed in chemical-induced fibrosis and MASH models, highlighting its potential as a therapeutic candidate for treating liver fibrosis."
Preclinical • Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Liver Failure • Metabolic Dysfunction-Associated Steatohepatitis • COL1A1 • GDF15 • IL6 • TGFB1 • TNFA
January 04, 2025
A novel GLP-1/GDF15 dual-agonist reduces hepatic inflammation and fibrosis in murine models of chemical-induced liver fibrosis and Metabolic Associated Steatohepatitis (MASH)
(APASL 2025)
- "GLP-1/GDF15 dual-agonist showed a synergistic effect in reducing hepatic inflammation and fibrosis was observed in chemical-induced fibrosis and MASH models, highlighting its potential as a therapeutic candidate for treating liver fibrosis."
Preclinical • Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Liver Failure • Metabolic Dysfunction-Associated Steatohepatitis • COL1A1 • GDF15 • IL6 • TGFB1 • TNFA
1 to 2
Of
2
Go to page
1